全文获取类型
收费全文 | 657篇 |
免费 | 28篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 13篇 |
妇产科学 | 11篇 |
基础医学 | 126篇 |
口腔科学 | 8篇 |
临床医学 | 46篇 |
内科学 | 126篇 |
皮肤病学 | 22篇 |
神经病学 | 111篇 |
特种医学 | 16篇 |
外国民族医学 | 4篇 |
外科学 | 70篇 |
综合类 | 2篇 |
预防医学 | 51篇 |
眼科学 | 11篇 |
药学 | 47篇 |
肿瘤学 | 18篇 |
出版年
2019年 | 11篇 |
2018年 | 8篇 |
2015年 | 8篇 |
2014年 | 8篇 |
2013年 | 14篇 |
2012年 | 9篇 |
2011年 | 25篇 |
2010年 | 14篇 |
2009年 | 9篇 |
2008年 | 19篇 |
2007年 | 26篇 |
2006年 | 16篇 |
2005年 | 24篇 |
2004年 | 22篇 |
2003年 | 22篇 |
2002年 | 21篇 |
2001年 | 27篇 |
2000年 | 28篇 |
1999年 | 35篇 |
1997年 | 6篇 |
1995年 | 6篇 |
1993年 | 6篇 |
1992年 | 15篇 |
1991年 | 8篇 |
1990年 | 6篇 |
1989年 | 8篇 |
1988年 | 6篇 |
1987年 | 7篇 |
1984年 | 8篇 |
1983年 | 6篇 |
1981年 | 8篇 |
1979年 | 8篇 |
1976年 | 5篇 |
1975年 | 10篇 |
1974年 | 9篇 |
1973年 | 6篇 |
1972年 | 7篇 |
1970年 | 5篇 |
1969年 | 8篇 |
1948年 | 5篇 |
1947年 | 7篇 |
1932年 | 4篇 |
1929年 | 5篇 |
1927年 | 4篇 |
1926年 | 4篇 |
1925年 | 5篇 |
1924年 | 8篇 |
1923年 | 8篇 |
1922年 | 16篇 |
1921年 | 4篇 |
排序方式: 共有686条查询结果,搜索用时 46 毫秒
61.
Opinion statement Aims of treatment for primary sclerosing cholangitis are as follows: prevention of progression of hepatobiliary disease, reduction
of symptoms and consequences of cholestasis (pruritus, osteoporosis), and prevention of complications (colorectal cancer,
hepatobiliary cancer). Ursodeoxycholic acid (UDCA) improves biliary secretion and laboratory parameters of cholestasis, but
its effects on liver histology and survival are not clear. It reduces the incidence of dysplasias and carcinomas of the colon
in patients with colitis and possibly has a beneficial effect on the incidence of bile duct carcinomas. At present, UDCA represents
the most promising therapeutic option. Immunosuppressive treatment has not been proven to be effective; it appears to be indicated
in the overlap syndrome with autoimmune hepatitis but may be harmful in bacterial cholangitis. Bacterial cholangitis is common
in patients with dominant stenoses and requires antibiotic treatment. Endoscopic treatment of dominant stenoses improves cholestasis
and prolongs survival in comparison to predicted survival. Pruritus represents a problem in some patients, and cholestyramine
represents the first-line treatment. If ineffective, opioid antagonists, rifampin, or ondansetron may be tried. For treatment
of osteoporosis and osteopenia, calcium and vitamin D supplementation are recommended, and in selected cases, bisphosphonates
may be indicated. In patients with severe cholestasis and coagulation defects, parenteral supplementation of vitamin K may
be indicated. During treatment, all patients should be regularly screened for colonic and bile duct carcinomas. Patients with
cirrhosis of the liver and its complications are treated accordingly, and in end-stage disease, liver transplantation is indicated. 相似文献
62.
Rost D Welker A Welker J Millonig G Berger I Autschbach F Schuppan D Mueller S 《Journal of hepatology》2007,46(3):482-491
BACKGROUND/AIMS: Reactive oxygen species (ROS), such as H2O2, are implicated in normal and pathological liver function. However, due to the lack of suitable in vivo models of ROS generation the (patho) physiological relevance of H2O2 remains controversial. METHODS: We established a novel model of sustained hepatic H2O2 release using intravenous administration of purified Aspergillus niger glucose oxidase (GOX) in rats. RESULTS: GOX is rapidly cleared from the blood stream and almost exclusively localizes to Kupffer cells. GOX maintained its ability to generate H2O2 over 24h. While sublethal GOX doses induced hepatocellular necrosis, our morphological and functional studies show that lower levels of GOX which generate H2O2 comparable to release by inflammatory cells are non-toxic and do not induce histological inflammation. However, these non-toxic H2O2 levels increased oxidized glutathione and induced heme oxygenase 1 in the liver. In addition, several hepatocyte transporters were downregulated, while no decrease of bile formation, a sensitive marker of liver function, was observed. CONCLUSIONS: Our in vivo model allows to study the effects of extracellular H2O2 in the liver as is released by inflammatory cells. Thus analysis of the role of this major ROS in the absence of confounding inflammatory cofactors will be possible. 相似文献
63.
Callewaere C Banisadr G Rostène W Parsadaniantz SM 《Journal of molecular endocrinology》2007,38(3):355-363
Chemokines are small secreted proteins that chemoattract and activate immune and non-immune cells both in vivo and in vitro. In addition to their well-established role in the immune system, several recent reports have suggested that chemokines and their receptors may also play a role in the central nervous system (CNS). The best known central action is their ability to act as immunoinflammatory mediators. Indeed, these proteins regulate leukocyte infiltration in the brain during inflammatory and infectious diseases. However, we and others recently demonstrated that they are expressed not only in neuroinflammatory conditions, but also constitutively by different cell types including neurons in the normal brain, suggesting that they may act as modulators of neuronal functions. The goal of this review is to highlight the role of chemokines in the control of neuroendocrine functions. First, we will focus on the expression of chemokines and their receptors in the CNS, with the main spotlight on the neuronal expression in the hypothalamo-pituitary system. Secondly, we will discuss the role--we can now suspect--of chemokines and their receptors in the regulation of neuroendocrine functions. In conclusion, we propose that chemokines can be added to the well-described neuroendocrine regulatory mechanisms, providing an additional fine modulatory tuning system in physiological conditions. 相似文献
64.
Goldstein JN Fazen LE Wendell L Chang Y Rost NS Snider R Schwab K Chanderraj R Kabrhel C Kinnecom C Fitzmaurice E Smith EE Greenberg SM Rosand J 《Neurocritical care》2009,10(1):28-34
Introduction Intracerebral hemorrhage (ICH) is the most feared complication of oral anticoagulant therapy (OAT). While anticoagulated patients
have increased severity of bleeding following ICH, they may also be at increased risk for thromboembolic events (TEs) given
that they had been prescribed OAT prior to their ICH. We hypothesized that TEs are relatively common following ICH, and that
anticoagulated patients are at higher risk for these complications.
Methods Consecutive patients with primary ICH presenting to a tertiary care hospital from 1994 to 2006 were prospectively characterized
and followed. Hospital records were retrospectively reviewed for clinically relevant in-hospital TEs and patients were prospectively
followed for 90 day mortality.
Results For 988 patients of whom 218 (22%) were on OAT at presentation, median hospital length of stay was 7 (IQR 4–13) days and 90-day
mortality was 36%. TEs were diagnosed in 71 patients (7.2%) including pulmonary embolism (1.8%), deep venous thrombosis (1.1%),
myocardial ischemia (1.6%), and cerebrovascular ischemia (3.0%). Mean time to event was 8.4 ± 7.0 days. Rates of TE were 5%
among those with OAT-related ICH and 8% among those with non-OAT ICH (P = 0.2). After multivariable Cox regression, the only independent risk factor for developing a TE was external ventricular
drain placement (HR 2.1, 95% CI 1.1–4.1, P = 0.03). TEs had no effect on 90-day mortality (HR 0.7, 95% CI 0.5–1.1, P = 0.1).
Conclusions The incidence of TEs in an unselected ICH population was 7.2%. Patients with OAT-related ICH were not at increased risk of
TEs. 相似文献
65.
66.
Guyon A Skrzydelski D Rovère C Apartis E Rostène W Kitabgi P Mélik Parsadaniantz S Nahon JL 《The European journal of neuroscience》2008,28(5):862-870
Dopaminergic neurons of the substantia nigra constitutively express the CXCR4 receptor for the chemokine stromal-cell-derived factor 1α (CXCL12) but, to date, no direct effect of CXCR4 activation by CXCL12 on membrane conductance of dopaminergic neurons has been demonstrated. We tested the effects of CXCL12 on whole-cell currents of dopaminergic neurons recorded in patch clamp in substantia nigra slices and showed that CXCL12 (0.01–10 n m ) increased the amplitude of total high-voltage-activated (HVA) Ca currents through CXCR4 activation. This effect was reversibly reduced by ϖ-conotoxin-GVIA, suggesting that CXCL12 acted on N-type Ca currents, known to be involved in dopamine (DA) release. We therefore investigated the effects of CXCL12 on DA release from cultured dopaminergic neurons from the rat mesencephalon. In basal conditions, CXCL12 alone had no effect on DA release. When neurons were depolarized with KCl (20 m m ), and thus when HVA Ca currents were activated, low CXCL12 concentrations (1–50 n m ) increased DA release via CXCR4 stimulation. These data strongly suggest that the chemokine CXCL12 can act directly as a neuromodulator of dopaminergic neuronal electrical activity through the modulation of HVA currents. 相似文献
67.
68.
Both tacrolimus (TAC) and sirolimus (SRL) bind to the same immunophilin FKBP12; however, their mechanisms of action are distinct. SRL inhibits mammalian target of rapamycin (TOR), which is an enzyme critical to the immune function. TOR inhibition blocks the signal that mediates T-cell proliferation by preventing cell-cycle progression from G1 to S phase. Moreover, TOR inhibition results in a decrease in antibody production by blocking B-cell proliferation and maturation into antibody producing cells. The use of SRL has resulted in a decrease in the number of rejection episodes. As with other immunosuppressive agents, SRL can cause dose-related side effects, the most notable of which are hypercholesterolemia, hyperlipidemia, anemia, and thrombocytopenia. Thus, therapeutic drug monitoring to assess efficacy and toxicity has became a necessity. SRL blood levels do not correlate with its bioactivity and are affected by the concomitant use of other immunosuppressive drugs. To determine the bioactivity of SRL we have developed an assay to determine the level of Sirolimus per lymphocyte of transplant patients. The levels were correlated with lymphocyte count. METHODS: Whole blood samples from patients on SRL were collected in Ethylene Diamine Tetra-acetic acid (EDTA) vacutainer tubes. Immediately the lymphocytes from 2 mL of blood were separated using 1.5 mL of Ficoll gradient, by centrifugation for 30 minutes at 2500 RPM. The lymphocytes were washed three times with phosphate-bufferd saline and the pellet suspended in 150 microL of Middle East research institute (MERI) drug extraction solution (Beirut, Lebanon), which was then added to 300 microL of IMx solublizing reagent. The cytoplasmic SRL concentrations in lymphocytes were measured using kits supplied from Abbott diagnostics or by high-performance liquid tomography. A corresponding whole blood sample from each patient was used to measure blood levels. To determine the level per lymphocyte, the value obtained was divided by the number of lymphocytes and expressed as Pg/cell. A pharmacokinetic profile for both blood and lymphocytes was constructed for each patient using data corresponding to predose C(0), 1 hour (C(1)) and 2 hours (C(2)) after the dose. The lymphocyte enumeration for C(0), C(1), and C(2) was performed using the FACS Calibur Flow Cytometer from Becton Dickinson. The average dose was 2.86 +/- 1.27 mg/d with a C(0) = 8.05 +/- 4.24, C(1) = 21.9 +/- 8.9 ng/mL, and C(2) = 23 +/- 0.03 ng/mL. Although there was a significant correlation (P=.0975) between the dose and C(0), there was no correlation between the dose and C(0) level on the lymphocyte count P=.897. However, there was a strong correlation between SRL lymphocyte levels (pg/cell) and the lymphocyte count (r(2)=.6.06). The higher the concentration of the drug the lower the lymphocyte counts. The assay is sensitive to within 0.45 pg/cell, reproducible with a coefficient of variance (CV) of 6.4% within assay and 7.5% for intraassay. 相似文献
69.
Mäki R Suihko E Rost S Heiskanen M Murtomaa M Lehto VP Ketolainen J 《Journal of pharmaceutical sciences》2007,96(2):438-447
In this study three model drugs (N-acetyl-D-glucosamine (NAG), anhydrous caffeine, and propranolol hydrochloride) were agglomerated with starch acetate (SA) by mixing the binary powders on a stainless steel (SS) plate. Agglomeration was induced by triboelectrification of the particles during mixing, and it was evaluated as a method to achieve controlled drug release rate. These agglomerates, mixed with different amounts of a disintegrant, were compressed into tablets whose dissolution characteristics were determined. Triboelectric measurements showed that when the drugs were in contact with SS, charges of the opposite polarity were generated to SA (+) and caffeine and NAG (-) promoting adhesion. Instead, propranolol HCl was charged with the same polarity as SA. SEM micrographs showed that smaller caffeine particles, in spite of their larger negative charge, agglomerated less efficiently with SA than larger NAG particles. This emphasizes the importance of particle size in the agglomeration process. Propranolol HCl did not form agglomerates with SA since their particle sizes and charges were identical. As a result, agglomeration of powders prior to tablet compression allows for modification and control of the release rate of the drugs from the SA matrix tablets as well as the tensile strength of the tablets. 相似文献
70.
Ohne Zusammenfassung 相似文献